1-3 of 3
Merve Kacar
Close
Sort by
Journal Articles

Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy

Fateeha Furqan, Katelin Baird, Merve Kacar, Annika S Surapaneni, Ulrich Kemmo Tsafack, Aniko Szabo, Jakub Svoboda, Brian T. Hill, Jason T. Romancik, Nirav N. Shah
Journal: Blood
Blood (2023) 142 (Supplement 1): 4486.
https://doi.org/10.1182/blood-2023-186703
Published: 2023
Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3087.
https://doi.org/10.1182/blood-2023-173943
Published: 2023
Journal Articles

Prescription Patterns of Initial Therapy and Outcomes of Elderly Hodgkin Lymphoma Patients. Toxicity and Efficacy Balance of Attenuated Initial Therapy

Merve Kacar, Robert M. Dean, Allison Winter, Brad Pohlman, Deepa Jagadeesh, Brian T. Hill, Paolo F. Caimi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6198.
https://doi.org/10.1182/blood-2023-190885
Published: 2023